Residency · Residency · Critical Care

Vasopressor and Inotrope Pharmacology

Adrenergic Receptor Physiology

Receptor Classification and Distribution

The rational use of vasoactive medications in critical care demands a thorough understanding of the adrenergic receptor system and its downstream signaling pathways. Alpha-1 receptors are expressed predominantly on vascular smooth muscle throughout the body, with particularly dense concentrations in the splanchnic, renal, and cutaneous vascular beds. Activation of alpha-1 receptors produces vasoconstriction, which is the primary mechanism by which many vasopressors elevate systemic vascular resistance and mean arterial pressure. Alpha-2 receptors serve a dual role: at presynaptic nerve terminals, they function as autoreceptors that inhibit norepinephrine release, forming the basis for central sympatholytic agents such as clonidine and dexmedetomidine, while at vascular smooth muscle, they contribute to vasoconstriction through a mechanism distinct from alpha-1 activation.

Beta-1 receptors are concentrated in the myocardium, where their activation increases chronotropy (heart rate), inotropy (contractile force), dromotropy (conduction velocity), and lusitropy (relaxation rate). These receptors are also found on juxtaglomerular cells in the kidney, where they stimulate renin release and activate the renin-angiotensin-aldosterone axis. Beta-2 receptors mediate vasodilation in vascular smooth muscle, bronchodilation in airway smooth muscle, and glycogenolysis in hepatocytes. The beta-3 receptor, less commonly discussed in clinical pharmacology, promotes lipolysis in adipose tissue and exerts a negative inotropic effect on the myocardium, functioning as a counterregulatory mechanism against excessive sympathetic stimulation. Dopaminergic receptors, specifically D1 and D2 subtypes, are located in the renal and mesenteric vasculature, where they mediate vasodilation. Despite theoretical appeal, dopaminergic receptor activation has no proven clinical benefit for renal protection.

Signal Transduction

The intracellular signaling cascades activated by these receptors explain both their physiological effects and the clinical phenomenon of tachyphylaxis. Alpha-1 receptors couple to Gq-proteins, which activate phospholipase C, generating inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from intracellular stores, producing smooth muscle contraction and vasoconstriction. In contrast, beta-1 and beta-2 receptors couple to Gs-proteins, which activate adenylyl cyclase to increase intracellular cyclic AMP (cAMP). cAMP activates protein kinase A (PKA), which phosphorylates calcium channels and other targets to increase contractility in the heart and produce vasodilation in vascular beds.

A critically important concept for the intensivist is receptor downregulation. Prolonged exposure to agonists causes beta-receptor internalization and desensitization, a process that explains the tachyphylaxis observed with sustained catecholamine infusions such as dobutamine. In critically ill patients, this phenomenon is compounded by a baseline reduction in adrenergic receptor density and coupling efficiency, which contributes to the catecholamine resistance frequently encountered in severe septic shock and other states of prolonged sympathetic activation.

Non-Adrenergic Vasoactive Receptors

Several clinically important vasoactive pathways operate entirely outside the adrenergic receptor system. The V1a vasopressin receptor, expressed on vascular smooth muscle, mediates vasoconstriction through the Gq/PLC/IP3 pathway, the same intracellular cascade used by alpha-1 receptors but via a completely independent receptor system. This redundancy is therapeutically exploitable: when adrenergic receptors are downregulated or desensitized, vasopressin can still produce vasoconstriction through V1a activation. The V2 receptor, located on renal collecting duct cells, promotes water reabsorption through aquaporin insertion and is primarily relevant to the antidiuretic effects of vasopressin. The AT1 angiotensin II receptor, found on vascular smooth muscle and the adrenal cortex, mediates potent vasoconstriction and stimulates aldosterone secretion, offering yet another catecholamine-independent mechanism for blood pressure support. Phosphodiesterase III, an intracellular enzyme that degrades cAMP in both myocardium and vascular smooth muscle, provides the pharmacological target for milrinone: inhibition of PDE III increases intracellular cAMP, producing combined inotropy and vasodilation.

<image>Comprehensive receptor pharmacology diagram showing five columns representing the major vasoactive receptor types (alpha-1, beta-1, beta-2, V1a, AT1). Each column shows: the receptor embedded in a cell membrane with its G-protein coupling, the intracellular signaling cascade (second messengers, kinases), and the physiological effect at the bottom (vasoconstriction, inotropy, vasodilation, etc.). Arrows connecting different drugs to their receptor targets with relative potency indicated by arrow thickness. Include norepinephrine, epinephrine, vasopressin, phenylephrine, dobutamine, dopamine, milrinone, and angiotensin II.</image>

Vasopressors

Norepinephrine

Norepinephrine is the cornerstone vasopressor in modern critical care and serves as the first-line agent for the vast majority of shock states. Its pharmacological profile features potent alpha-1 agonism with moderate beta-1 activity and minimal beta-2 effect, producing a hemodynamic signature characterized by increased systemic vascular resistance, elevated mean arterial pressure, a mild increase in cardiac output, and relatively little change in heart rate. This combination of vasoconstrictive and modest inotropic effects makes norepinephrine uniquely suitable as a first-line agent across distributive, cardiogenic, and mixed shock phenotypes.

Dosing typically begins at 0.05 to 0.5 mcg/kg/min and can be titrated broadly within a range of 0.01 to 3 mcg/kg/min without a defined maximum dose. The Surviving Sepsis Campaign 2021 guidelines provide a strong recommendation for norepinephrine as the first-line vasopressor in septic shock, a position supported by the landmark SOAP II trial, which demonstrated that norepinephrine was associated with fewer arrhythmias than dopamine and with lower mortality in the cardiogenic shock subgroup. An important practical consideration is the safety of peripheral administration: norepinephrine can be safely infused through a proximal intravenous catheter at or above the antecubital fossa for up to 24 hours, with an extravasation risk of less than 2 percent. When extravasation does occur, treatment with phentolamine, 5 to 10 mg diluted in 10 mL of normal saline injected locally within 12 hours, can prevent tissue necrosis.

Vasopressin (Arginine Vasopressin, ADH)

Vasopressin acts on V1a receptors to produce vasoconstriction, on V2 receptors to promote water retention, and on V3 (V1b) receptors in the anterior pituitary to stimulate ACTH release. A key physiological observation is that endogenous vasopressin stores are depleted early in septic shock, creating a state of relative vasopressin deficiency that can be therapeutically targeted with exogenous replacement. Vasopressin is administered at a fixed dose, most commonly 0.03 to 0.04 units per minute, and unlike norepinephrine, it is not titrated to hemodynamic effect in most protocols.

The landmark VASST trial of 2008 demonstrated no overall mortality difference between norepinephrine plus vasopressin and norepinephrine alone, although a possible benefit was observed in the subgroup of patients with less severe septic shock requiring norepinephrine at doses below 15 mcg per minute. The VANISH trial of 2016 similarly found no mortality difference when vasopressin was used as a first-line agent compared to norepinephrine, though a reduced need for renal replacement therapy was observed in the vasopressin group. The principal advantages of vasopressin lie in its independence from adrenergic receptors, making it effective in catecholamine-resistant vasoplegia, and its relatively modest effect on pulmonary vascular resistance compared to norepinephrine. Clinicians must remain vigilant for complications including digital ischemia, mesenteric ischemia, and hyponatremia, the last of which is mediated by V2 effects at higher doses.

Epinephrine

Epinephrine is a potent and pleiotropic catecholamine with significant agonist activity at alpha-1, beta-1, and beta-2 receptors. Its hemodynamic effects are dose-dependent in a manner that is clinically important to understand: at lower doses (below approximately 0.1 mcg/kg/min), beta effects predominate, producing increased inotropy and chronotropy, while at higher doses, alpha-mediated vasoconstriction becomes the dominant hemodynamic effect. This dual pharmacology makes epinephrine useful as a combined vasopressor-inotrope, but it also introduces complications that limit its role as a first-line agent.

The CAT trial demonstrated no mortality difference between epinephrine and the combination of norepinephrine plus dobutamine, but the epinephrine group exhibited more metabolic derangements. One particularly important adverse effect is epinephrine's ability to increase aerobic lactate production through beta-2-mediated glycogenolysis in skeletal muscle. This pharmacological hyperlactatemia can confound the use of lactate as a marker of tissue perfusion and lead to inappropriate escalation of resuscitation. Epinephrine also decreases splanchnic perfusion at higher doses. For these reasons, it is generally reserved as a second-line vasopressor or is employed when a combined vasopressor-inotrope effect is desired and the clinician is aware of its limitations in lactate interpretation.

Phenylephrine

Phenylephrine is a pure alpha-1 agonist that increases systemic vascular resistance and mean arterial pressure without direct beta-receptor-mediated effects. Because it increases afterload without augmenting contractility, phenylephrine may actually decrease cardiac output, which is a significant liability in the ICU setting where most patients have some degree of myocardial compromise. Its role in the intensive care unit is limited, and it should be avoided in cardiogenic shock and septic shock with myocardial depression. The clinical scenarios in which phenylephrine retains utility include supraventricular tachycardia with hypotension, where its reflex bradycardic effect is therapeutically advantageous, neuraxial hypotension following spinal or epidural anesthesia, and as a brief temporizing agent while central access is being established.

Angiotensin II

Angiotensin II represents a pharmacologically distinct approach to vasoconstriction, acting through AT1 receptors to produce vasoconstriction and stimulate aldosterone and ADH release. The ATHOS-3 trial of 2017 demonstrated a markedly improved MAP response at 3 hours in patients with refractory vasodilatory shock, with 70 percent of angiotensin II-treated patients achieving the target MAP compared to only 23 percent of controls. Dosing begins at 20 ng/kg/min and is titrated to MAP effect within a typical range of 1.25 to 40 ng/kg/min.

The clinical appeal of angiotensin II lies in its complete independence from both the adrenergic and vasopressin receptor systems, providing a third axis of vasoconstriction that can be recruited when the other two are exhausted or desensitized. Post-hoc analyses of the ATHOS-3 data have suggested particular benefit in patients on renal replacement therapy and those with elevated renin levels, potentially reflecting a subset with activated renin-angiotensin physiology. The primary risk associated with angiotensin II is thromboembolic events, and concurrent venous thromboembolism prophylaxis is mandatory during its use.

Dopamine

Dopamine has a complex dose-dependent pharmacology that has historically been described as activating dopaminergic receptors at 1 to 3 mcg/kg/min, beta-1 receptors at 3 to 10 mcg/kg/min, and alpha-1 receptors at doses exceeding 10 mcg/kg/min. However, this classic dose-response paradigm is now recognized as oversimplified, with significant overlap and individual variability across the dose ranges. The concept of "renal-dose dopamine," based on the theory that low-dose dopaminergic activation would protect against acute kidney injury, has been definitively debunked by the work of Bellomo and others and should be considered an abandoned practice.

The SOAP II trial demonstrated a significantly increased arrhythmia risk with dopamine compared to norepinephrine, 24 percent versus 12 percent, which has been one of the primary drivers of its displacement from first-line status. Current guidelines do not recommend dopamine as a first-line vasopressor in septic shock or other forms of distributive shock. Its remaining clinical niche is narrow, limited to highly selected patients with bradycardia and hypotension in whom the chronotropic effect of dopamine may be specifically desired.

<image>Comparative vasopressor dose-response chart showing six vasopressors (norepinephrine, vasopressin, epinephrine, phenylephrine, dopamine, angiotensin II) along the y-axis. For each agent, horizontal bars showing dose ranges with color gradients indicating predominant receptor activation at each dose range (blue for alpha, red for beta, green for dopaminergic, purple for V1, orange for AT1). Adjacent columns showing key hemodynamic effects (MAP, CO, HR, SVR) with up/down arrows indicating magnitude of effect. Include a "preferred clinical scenario" column listing best use case for each agent.</image>

Inotropes

Dobutamine

Dobutamine is a synthetic catecholamine engineered to provide predominantly beta-1 agonism with additional beta-2 and weak alpha-1 activity. This receptor profile produces a hemodynamic signature of increased cardiac output, increased stroke volume, decreased systemic vascular resistance due to the net beta-2 vasodilatory effect, and potentially decreased pulmonary artery occlusion pressure. The net result is an agent that augments forward flow while reducing afterload, making it particularly well-suited for conditions in which impaired contractility is the primary hemodynamic derangement.

Dobutamine is dosed from 2 to 20 mcg/kg/min, typically initiated at 2 to 5 mcg/kg/min and titrated to hemodynamic effect. Its primary indication in the ICU is septic cardiomyopathy with persistent hypoperfusion despite adequate volume resuscitation and vasopressor support. Importantly, dobutamine should not be used to target supranormal oxygen delivery, a strategy that was popular in earlier decades but has been shown to provide no benefit and possibly cause harm. The major risks of dobutamine include tachycardia, arrhythmias, increased myocardial oxygen demand, and hypotension at low doses due to unopposed beta-2-mediated vasodilation. A clinically important limitation is the development of tachyphylaxis within 48 to 72 hours, caused by beta-receptor downregulation, which progressively diminishes the drug's effectiveness with sustained infusion.

Milrinone

Milrinone operates through an entirely different mechanism than the catecholamine inotropes, inhibiting phosphodiesterase III to increase intracellular cAMP independently of the beta-receptor. This bypass of the beta-receptor confers two important clinical advantages: milrinone remains effective in the presence of beta-blocker therapy, and it does not exhibit tachyphylaxis. Its combined inotropic and vasodilatory effects earn it the designation of "inodilator," and its ability to reduce pulmonary vascular resistance makes it particularly valuable in right ventricular failure associated with pulmonary hypertension.

Milrinone is dosed at 0.125 to 0.75 mcg/kg/min, with a loading dose of 50 mcg/kg over 10 minutes that is frequently omitted in the ICU because of the risk of significant hypotension. The principal disadvantages of milrinone relate to its long half-life of 2.3 hours, which is further prolonged in renal failure, making dose titration less responsive than with catecholamine agents. It is also more hypotension-prone and arrhythmogenic than dobutamine. The OPTIME-CHF trial demonstrated no benefit and a trend toward harm with milrinone in ischemic heart failure, limiting its use in that population. The primary clinical roles for milrinone are right ventricular failure with pulmonary hypertension and post-cardiotomy low output syndrome.

Levosimendan

Levosimendan is a calcium sensitizer that increases myocardial contractility by binding to troponin C and enhancing the sensitivity of the contractile apparatus to existing intracellular calcium, without increasing calcium levels themselves. This mechanism theoretically avoids the increased myocardial oxygen demand associated with agents that raise intracellular calcium. Levosimendan also inhibits PDE III and opens ATP-sensitive potassium channels, contributing additional inotropic and vasodilatory effects. Its pharmacokinetics are distinctive: an active metabolite, OR-1896, sustains hemodynamic effects for 7 to 9 days after a single 24-hour infusion.

Despite its elegant pharmacology, levosimendan has failed to demonstrate clinical benefit in the settings where it has been most extensively studied. The LeoPARDS trial of 2016 found no benefit in septic shock, with increased supraventricular tachyarrhythmias in the treatment group, and the LEVO-CTS trial of 2017 showed no benefit in post-cardiac surgery low output syndrome. The best evidence for levosimendan currently exists in decompensated chronic heart failure and possibly in right ventricular failure associated with pulmonary hypertension.

Isoproterenol

Isoproterenol is a pure beta-1 and beta-2 agonist with no alpha activity, producing increased heart rate, enhanced contractility, and decreased systemic vascular resistance. Its clinical applications are narrow and specific: pharmacological stress testing, management of torsades de pointes through heart rate acceleration, treatment of symptomatic bradycardia refractory to atropine and pacing, and beta-blocker overdose. It is dosed at 2 to 20 mcg per minute and is not a routine agent in the management of shock.

Special Considerations

Vasopressor-Refractory Shock

Vasopressor-refractory shock, defined as the inability to achieve a MAP of 65 mmHg despite norepinephrine doses exceeding 0.5 mcg/kg/min or equivalent with adequate volume resuscitation, represents one of the most challenging clinical scenarios in critical care. A systematic stepwise approach is essential: after maximizing norepinephrine, the addition of vasopressin at 0.03 to 0.04 units per minute is the standard second step, followed by angiotensin II and hydrocortisone at 200 mg per day. Before escalating vasoactive doses further, the clinician must actively evaluate for correctable causes including adrenal insufficiency, occult hemorrhage, uncontrolled source of sepsis, cardiac tamponade, and tension pneumothorax.

When these measures fail, several salvage strategies merit consideration. Methylene blue, administered as a 1 to 2 mg/kg intravenous bolus, inhibits the guanylyl cyclase and nitric oxide pathway and has been supported by case series although no randomized controlled trials exist. Hydroxocobalamin at 5 g intravenously acts as a nitric oxide scavenger and has been employed in post-cardiopulmonary bypass vasoplegia. Thiamine at 200 mg intravenously may improve lactate clearance, though evidence remains insufficient to support routine use.

Peripheral Vasopressor Administration

The traditional teaching that vasopressors require central venous access has been challenged by emerging evidence supporting the safety of peripheral administration for short durations. The VITAMIN and PRESEP trials support the safety of peripheral norepinephrine when administered through proximal veins at or above the antecubital fossa using 18-gauge or larger catheters. Extravasation rates with close monitoring range from 2 to 5 percent, and most cases are mild and self-limiting. This evidence has important implications for clinical practice, as it removes a barrier to early vasopressor initiation: resuscitation should not be delayed by the need to establish central venous access. Peripheral vasopressor administration is contraindicated in distal small veins such as the hand or foot and in patients with known peripheral vascular disease.

Catecholamine Toxicity

The concept of catecholamine toxicity has gained increasing attention as evidence mounts that excessive and prolonged catecholamine exposure is independently harmful. Beta-1 stimulation drives calcium overload in cardiomyocytes, leading to myocyte injury, myocardial stunning, and troponin elevation. Additional deleterious effects include tachyarrhythmias, immunosuppression, and metabolic derangements. This growing recognition has given rise to the concept of "decatecholaminization," a strategy that seeks to minimize total catecholamine exposure by employing non-adrenergic agents such as vasopressin and angiotensin II earlier in the hemodynamic management algorithm. A provocative pilot study by Morelli and colleagues demonstrated that short-acting beta-blockade with esmolol in septic shock patients with persistent tachycardia above 120 beats per minute was associated with improved mortality, though this finding has not yet been confirmed in a larger randomized controlled trial.

<image>Clinical decision algorithm for vasopressor and inotrope selection in the ICU. Starting node: "Hemodynamic instability requiring vasoactive support." First branch: shock type determination (distributive, cardiogenic, mixed). Distributive pathway: NE first-line → if refractory add vasopressin → if still refractory consider angiotensin II + hydrocortisone → if still refractory methylene blue. Cardiogenic pathway: branches into LV failure (NE + dobutamine, consider MCS) and RV failure (NE + milrinone or inhaled epoprostenol, avoid volume overload). Mixed shock: NE + inotrope selection based on predominant pathology. Include dose ranges at each node, specific hemodynamic targets, and red flag criteria for escalation.</image>

Key Clinical Pearls

• Norepinephrine is the first-line vasopressor in septic, cardiogenic, and most other forms of shock — phenylephrine and dopamine should be avoided
• Vasopressin at fixed dose (0.03-0.04 U/min) is the preferred second-line agent; it is NOT titrated like norepinephrine
• Epinephrine increases aerobic lactate production — do not chase epinephrine-induced hyperlactatemia with additional fluid
• Dobutamine is the first-line inotrope for septic cardiomyopathy; milrinone is preferred when beta-blocker effects or RV failure/PH are present
• Angiotensin II offers a catecholamine-independent vasoconstriction pathway and may be especially useful in patients on RRT
• Renal-dose dopamine does not exist — this practice should be abandoned
• Peripheral vasopressor administration via proximal veins is safe for short durations and should not delay vasopressor initiation
• Always address underlying etiology and adjunct therapies (hydrocortisone, source control) before maximizing vasopressor doses

References

1. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-789.
2. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877-887.
3. Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419-430.
4. Gordon AC, Perkins GD, Singer M, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med. 2016;375(17):1638-1648.
5. Overgaard CB, Dzavik V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation. 2008;118(10):1047-1056.

Read this lecture as Markdown